1. Home
  2. TTRX vs DAVI Comparison

TTRX vs DAVI Comparison

Compare TTRX & DAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$10.09

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

DAVI

Davion Healthcare Plc Ordinary Shares

N/A

Current Price

$1.55

Market Cap

291.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
DAVI
Founded
2015
2022
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
291.3M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
TTRX
DAVI
Price
$10.09
$1.55
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
83.7K
★ 772.6K
Earning Date
11-25-2026
04-06-2027
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$1.65
52 Week High
$16.45
$6.05

Technical Indicators

Market Signals
Indicator
TTRX
DAVI
Relative Strength Index (RSI) 42.31 5.49
Support Level $10.05 N/A
Resistance Level $10.72 N/A
Average True Range (ATR) 0.78 0.68
MACD -0.02 -0.48
Stochastic Oscillator 29.98 1.74

Price Performance

Historical Comparison
TTRX
DAVI

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: